Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ingredient Studies Again Not Enough For New Nordic Product Claims – NAD

This article was originally published in The Tan Sheet

Executive Summary

Two months after referring advertising for its Hair Volume supplement to FTC, NAD zeroes in on claims for New Nordic USA's Skin Care Collagen Filler supplement. NAD says the firm should discontinue anti-wrinkle and collagen-building claims in the absence of reliable evidence from well-controlled human clinical testing.

You may also be interested in...



Rejecting Nootrobox Cognitive Supplement Claims A No-Brainer For NAD

Cognitive supplements marketer Nootrobox discontinues claims for three of its products because the science supporting the ingredients in the formulas did not also support the products.

NAD Tugs On FTC's Sleeve Again About New Nordic Supplement Claims

New Nordic says it is reformulating its Skin Care Collagen Filler supplement and updating ad claims to more closely reflect its testing, but NAD says the firm is not complying with its recommendations. NAD refers New Nordic claims to FTC for the second time in six months.

GSK/Novartis Support For Benefiber Claims Too Thin To Convince NARB

Referring to rather than providing two studies was GSK/Novartis' downfall in arguing before the National Advertising Review Board to support Benefiber regularity claims. GSK/Novartis questions the panel’s "refusal to accept the full translations of two confirmatory studies referred to in the record."

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel